About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Maryland | 23,284 Studies Near You | Clareo Health

Clinical Trials LocationsMaryland

Clinical Trials in Maryland

Discover 23,284 clinical trials near Maryland. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 5181-5200 of 23,284 trials

COMPLETEDPhase 217 miles

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

NCT04629508

This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.

MyelofibrosisPolycythemia VeraThrombocythemia

Incyte Corporation4 participantsStarted Jul 2021

New Orleans, Louisiana, United States • Bethesda, Maryland, United States • Kansas City, Missouri, United States +18 more locations

TERMINATEDPhase 219 miles

Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US

NCT05211284

Saroglitazar Magnesium 4 mg for NAFLD in People Living with HIV in the US

Nonalcoholic Fatty Liver Disease

Zydus Therapeutics Inc.4 participantsStarted Dec 2022

Birmingham, Alabama, United States • La Jolla, California, United States • San Francisco, California, United States +5 more locations

Find Trials by Condition in Maryland

Breast Cancerin Maryland Lung Cancerin Maryland Prostate Cancerin Maryland Colorectal Cancerin Maryland Melanomain Maryland Leukemiain Maryland Lymphomain Maryland Pancreatic Cancerin Maryland Ovarian Cancerin Maryland Brain Cancerin Maryland Diabetes

Data from ClinicalTrials.govTerms

Active Not RecruitingPhase 319 miles

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

NCT03635788

The purpose of this study was to compare the efficacy, safety, and durability of two different strategies to treat participants with a history of sub-optimal adherence and control of their HIV infection: long-acting (LA) antiretroviral therapy (ART) and all-oral standard of care (SOC).

National Institute of Allergy and Infectious Diseases (NIAID)456 participantsStarted Mar 2019

Birmingham, Alabama, United States • Los Angeles, California, United States • Los Angeles, California, United States +30 more locations

COMPLETEDPhase 319 miles

Long-Term Evaluation of BIIB067 (Tofersen)

NCT03070119

The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB067 (tofersen) in participants with amyotrophic lateral sclerosis (ALS) and confirmed superoxide dismutase 1 (SOD1) mutation. The secondary objectives are to evaluate the pharmacokinetic (PK), pharmacodynamic (PD), biomarker effects, and efficacy of BIIB067 administered to participants with ALS and a confirmed SOD1 mutation.

ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

Biogen139 participantsStarted Mar 2017

Phoenix, Arizona, United States • La Jolla, California, United States • San Francisco, California, United States +27 more locations

COMPLETEDPhase 4107 miles

Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

NCT05207865

The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.

MigraineEpisodic MigrainePhonophobia+1 more

Pfizer441 participantsStarted Mar 2022

Phoenix, Arizona, United States • Hawthorne, California, United States • North Hollywood, California, United States +16 more locations

SUSPENDED107 miles

INSPIRIS RESILIA Aortic Valve, Valve-in-Valve Surveillance Study

NCT04902053

The primary objective of the INSPIRIS RESILIA Aortic Valve-in-valve (ViV) Surveillance Study ("the Study") is to capture Adverse Event information and valve measurement data from dysfunctional INSPIRIS RESILIA aortic valves before and after Valve-in-valve (ViV) treatment.

Aortic Valve Replacement

Edwards Lifesciences50 participantsStarted Jun 2028

Los Angeles, California, United States • Gainesville, Florida, United States • Orlando, Florida, United States +4 more locations

Active Not RecruitingPhase 2107 miles

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

NCT06307431

The primary objective of the study is to compare intismeran autogene plus pembrolizumab to placebo plus pembrolizumab in participants with renal cell carcinoma (RCC) with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that intismeran autogene plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS.

Renal Cell Carcinoma

Merck Sharp & Dohme LLC272 participantsStarted Apr 2024

Duarte, California, United States • Los Angeles, California, United States • San Francisco, California, United States +60 more locations

RECRUITINGPhase 1/2115 miles

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

NCT06382168

This Phase I/II trial evaluates the safety and preliminary efficacy of DFP-10917 combined with venetoclax in relapsed or refractory acute myeloid leukemia. DFP-10917 is given as a 14-day continuous IV infusion every 28 days, alongside a 14-day oral course of venetoclax following an initial dose ramp-up. The initial phase tests a starting dose of 4 mg/m²/day of DFP-10917 with 400 mg daily of venetoclax. The Data Monitoring Committee reviews toxicity after one treatment cycle. If DLTs are minimal, more patients are added to confirm safety. If the lower dose level shows tolerability, it proceeds to the Phase II expansion to assess the treatment's effectiveness against leukemia using a Simon's two-stage design, targeting up to 17 participants.

Leukemia, Myeloid, Acute

Delta-Fly Pharma, Inc.39 participantsStarted Jun 2024

Orange, California, United States • Winston-Salem, North Carolina, United States • Burlington, Vermont, United States +1 more locations

COMPLETEDPhase 1132 miles

MR Image Synthesis With Low Gadobutrol Dose and AI

NCT06224543

Study 22403 is a Phase 1 / Proof of Concept exploratory investigation to assess the non-inferiority of low dose gadobutrol and SubtleGAD™, a software medical device using an Artificial Intelligence (AI) deep learning-based method to enhance the contrast signal from images acquired with low dose administration of gadobutrol (GAD) contrast. The primary objective is to demonstrate noninferiority of synthesized Central Nervous System (CNS) magnetic resonance (MR) images for 1 or 2 different gadobutrol-enhanced low-dose groups (0.01mmol/kg, and0.025 mmol/kg) compared to gadobutrol-enhanced CNS MR images at a standard dose of 0.1 mmol/kg. This investigation is a prospective, randomized, open label, multi-center study with blinded reads in participants with known or highly suspected CNS pathology. There will be at least 60 participants enrolled (30 per study arm). SubtleGAD will be used as a post-processing tool, prior to blinded read assessment of MR images acquired in either arm of the study.

Enhancing Brain Lesions

Subtle Medical60 participantsStarted Jun 2023

Peoria, Illinois, United States • Worcester, Massachusetts, United States • Rochester, Minnesota, United States +2 more locations

COMPLETEDPhase 2159 miles

Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women

NCT06308614

The goal of this clinical trial is investigating estetrol (E4) in women after menopause, suffering from sexual arousal disorder. The main question it aims to answer is: is 20 mg estetrol monohydrate effective in the treatment of sexual arousal disorder in women after their menopause. Participants will visit the clinic 7 times and complete a daily diary while receiving estetrol or placebo for 12 weeks. Placebo is a pill that looks the same as estetrol but has no active ingredient. Researchers will compare estetrol and placebo to see if estetrol has an effect on the sexual arousal of the participants.

Sexual Dysfunction, Physiological

Estetra82 participantsStarted Jan 2024

Mesa, Arizona, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +21 more locations

COMPLETEDPhase 3160 miles

Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease

NCT05085275

A 9-month randomized, double-blind, placebo-controlled study to compare the effect of fixed dose ferric citrate versus placebo in patients with advanced chronic kidney disease (eGFR ≤20 ml/min/1.73m2) on the composite endpoint of time to initiation of maintenance dialysis or all-cause mortality.

Anemia, Iron DeficiencyHyperphosphatemiaRenal Insufficiency, Chronic+4 more

USRC Kidney Research289 participantsStarted Mar 2022

Pine Bluff, Arkansas, United States • Chula Vista, California, United States • El Centro, California, United States +20 more locations

Enrolling By Invitation187 miles

Effect of Treatment Modality on Psychosocial Functioning of Survivors of Unilateral Retinoblastoma

NCT03662776

The purpose of this study is to find out about the quality of life and health in patients who had retinoblastoma in one eye (unilateral retinoblastoma), who either received treatment with chemotherapy injected directly into an artery leading to the eye (intra-arterial chemotherapy) or removal of the eye (enucleation). By quality of life, the investigators mean how the participants are feeling about being satisfied with things in their life, including, physical health, emotional health, and their ability to carry out daily activities. The investigators want to see if either treatment option would affect quality of life differently. The investigators hope that this information will help us provide better care to future children with retinoblastoma and better follow-up care for survivors of retinoblastoma.

Survivors of Unilateral Retinoblastoma

Memorial Sloan Kettering Cancer Center120 participantsStarted Aug 2018

New York, New York, United States • Houston, Texas, United States

RECRUITINGNA187 miles

CorMatrix Cor TRICUSPID ECM Valve Replacement - Pivotal Study

NCT05742906

The goal of this pivotal study is to demonstrate the safety and performance of the Cor TRICUSPID ECM (extracellular matrix) Valve (or Cor PEDIATRIC Tricuspid ECM Valve) for the surgical management of tricuspid valve disease and dysfunction in adult and pediatric patients. The main question(s) it aims to answer are: * whether the device may be implanted successfully and safely, and * whether the device effectively treats tricuspid valve disease and dysfunction through 12 months Participants will undergo: * preoperative evaluation * tricuspid valve replacement with the Cor TRICUSPID ECM Valve * postoperative evaluation, including at hospital discharge, 30 days, 6 months, and 12 months, and then annually thereafter through 5 years

Tricuspid Valve DiseaseTricuspid Valve Insufficiency

Corvivo Cardiovascular, Inc.92 participantsStarted Aug 2022

Indianapolis, Indiana, United States • New York, New York, United States

Active Not RecruitingPhase 2187 miles

A Study of Abemaciclib in Recurrent Glioblastoma

NCT02981940

This research study is studying a targeted therapy as a possible treatment for recurrent glioblastoma (GBM). The following intervention will be used in this study: -Abemaciclib

Dana-Farber Cancer Institute45 participantsStarted Feb 2017

Los Angeles, California, United States • San Francisco, California, United States • Boston, Massachusetts, United States +4 more locations

TERMINATEDPhase 2203 miles

A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

NCT05161481

This study is open to adults with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver). The purpose of this study is to find out whether a medicine called Avenciguat helps people with this condition. Participants are put into 3 groups randomly, which means by chance. Participants in 2 groups take different doses of Avenciguat as tablets twice a day. Participants in the placebo group take placebo as tablets twice a day. Placebo tablets look like Avenciguat tablets but do not contain any medicine. Participants are in the study for about 8 months. During this time, they visit the study site about 14 times. At 3 of the visits, the doctors check the pressure in a liver vein. This is done with a catheter (a long thin tube) and gives information about the pressure in the portal vein. The change in blood pressure is then compared between the groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Hypertension, Portal

Boehringer Ingelheim80 participantsStarted Apr 2022

Pasadena, California, United States • Rialto, California, United States • Miami Lakes, Florida, United States +42 more locations

COMPLETEDPhase 4308 miles

Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery

NCT03900026

The purpose of this study is to determine if evolocumab added to regular statin therapy improves vein graft patency after coronary artery bypass graft (CABG) surgery.

Coronary Artery Bypass Graft SurgeryAtherosclerosisVein Occlusion

Unity Health Toronto782 participantsStarted May 2019

San Francisco, California, United States • Jacksonville, Florida, United States • Portland, Maine, United States +19 more locations

Active Not RecruitingPhase 4348 miles

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

NCT01896479

The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC. It will test if the lower dose results in similar progression free survival (PFS) and overall response rate (ORR) with fewer adverse events compared to the PFS, ORR and adverse events found in previous clinical trials of 140 mg.

Medullary Thyroid Cancer

Exelixis247 participantsStarted Feb 2015

St Leonards, New South Wales, Australia • Herston, Queensland, Australia • Kurralta Park, South Australia, Australia +46 more locations

SUSPENDEDPhase 1377 miles

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

NCT04418167

This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.

JS InnoPharm, LLC71 participantsStarted Jun 2020

Phoenix, Arizona, United States • Tucson, Arizona, United States • San Francisco, California, United States +4 more locations

COMPLETEDPhase 2721 miles

A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

NCT05323656

The primary objective of this study is to compare the change in tumour size per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) in recurrent or metastatic SCCHN patients treated with setanaxib and pembrolizumab versus patients treated with placebo and pembrolizumab.

Squamous Cell Carcinoma of Head and Neck

Calliditas Therapeutics Suisse SA55 participantsStarted Apr 2022

Miami Beach, Florida, United States • City of Saint Peters, Missouri, United States • Creve Coeur, Missouri, United States +21 more locations

Active Not RecruitingPhase 1/2781 miles

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

NCT07150104

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat, pomalidomide, and dexamethasone and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).

Multiple Myeloma

GlaxoSmithKline14 participantsStarted Aug 2022

Salvador, Estado de Bahia, Brazil • Porto Alegre, Rio Grande do Sul, Brazil • Halifax, Nova Scotia, Canada +7 more locations

PreviousPage 260 of 1165Next

in Maryland

Heart Diseasein Maryland